鼻咽癌幸存者放疗后疲劳:结合患者报告与观察者评级的剂量学分析
80例无病鼻咽癌幸存者在放疗后完成MDASI-HN量表,其中56例可获取剂量学数据,分析10个MRI定义的潜在疲劳相关结构的剂量与慢性疲劳关系。递归分割分析发现垂体V52 Gy≥16%与慢性疲劳相关,作者推荐在计划优化时尽可能将垂体Dmax限制在<54 Gy、V52 Gy限制在<16%,尤其对年轻患者。
要点
- 56例鼻咽癌幸存者中,54%报告疲劳(MDASI-HN-F),59%按CTC-AE有疲劳。
- 慢性疲劳患者垂体Dmax和Dmean显著更高(p≤0.01)。
- 作者推荐垂体Dmax<54 Gy且V52 Gy<16%,尤其年轻患者。
核心结论
- 在垂体腺发现了剂量-疲劳关系,患者报告和观察者评级均支持。
- 作者推荐在计划优化时尽可能将垂体Dmax限制在<54 Gy、V52 Gy限制在<16%,尤其对年轻鼻咽癌患者。
研究设计与样本
- 80例无病鼻咽癌幸存者在放疗后完成MDASI-HN量表,疲劳由MDASI-HN疲劳条目和CTC-AE v3.0在放疗后6至36个月评估以确定慢性疲劳。
- 56例患者可获取颅底MRI和计划CT/放疗剂量,提取10个MRI定义的潜在疲劳相关结构的剂量学数据:脑干、垂体腺、下丘脑、基底节、内囊、松果体、丘脑底核、丘脑、黑质和海马。
- 采用递归分割分析识别与慢性疲劳相关的剂量-体积效应。
主要发现
- 56例组成队列,30例(54%)按MDASI-HN-F报告任何疲劳,33例(59%)按CTC-AE有任何疲劳。
- 垂体腺、脑干、海马和下丘脑的最大点剂量在疲劳患者中数值更高。
- 慢性疲劳患者垂体腺的Dmax和Dmean显著更高,p≤0.01。
- 递归分割分析识别出垂体V52 Gy≥16%的剂量-体积阈值(LogWorth 2.4,AUC 0.7),在年轻患者(<53岁)中观察到对垂体剂量的潜在敏感性。
关键数值与推荐
- 垂体V52 Gy≥16%(LogWorth 2.4,AUC 0.7)为递归分割分析识别的剂量-体积阈值。
- 作者推荐垂体Dmax<54 Gy且V52 Gy<16%,尤其年轻鼻咽癌患者,在可实现时于计划优化中执行。
临床怎么用
- 作者推荐在计划优化时尽可能将垂体Dmax限制在<54 Gy、V52 Gy限制在<16%,尤其对年轻鼻咽癌患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To explore for fatigue-related regions and the radiotherapy (RT) dose-fatigue relationship in nasopharyngeal cancer (NPC) survivors. METHODS: Eighty disease-free NPC survivors completed the MD Anderson Symptom Inventory-Head and Neck module (MDASI-HN) after RT. Fatigue was evaluated by the MDASI-HN fatigue item (MDASI-HN-F) and Common Terminology Criteria for Adverse Events v3.0 (CTC-AE), between 6 and 36 months after RT to determine the presence of chronic fatigue. Skull base MRIs and planning CT/RT dose were retrievable for 56 patients. Dosimetric data were extracted for 10 MRI-defined potential fatigue at-risk structures (FARS): brainstem (BS), pituitary gland (PG), hypothalamus (HT), basal ganglia, internal capsule, pineal gland, sub-thalamic nuclei, thalamus, substantia nigra, and hippocampus (HC). Recursive partitioning analysis (RPA) was used to identify dose-volume effects associated with chronic fatigue. RESULTS: 56 pts formed the cohort. Thirty patients (54%) reported any fatigue per MDASI-HN-F. Thirty-three pts (59%) had any fatigue by CTC-AE. The maximum point doses (Dmax) for PG, BS, HC, and HT were numerically higher in patients with fatigue. Dmax and Dmean of the PG were significantly higher in patients with chronic fatigue, p ≤ 0.01. A dose-volume threshold of PG V52 Gy ≥16% (LogWorth 2.4, AUC 0.7) was identified on RPA, and potential sensitivity to the PG doses was observed in younger patients (<53 years-old). CONCLUSION: A dose-fatigue relationship was identified for the pituitary gland, both patient-reported and observer ratings. We recommend limiting the Dmax of PG to <54 Gy and V52 Gy to <16%, particularly in young NPC patients, during plan optimization when achievable.
引用
- Fatigue following radiation therapy in nasopharyngeal cancer survivors: A dosimetric analysis incorporating patient report and observer rating. Radiother Oncol. 2019. PMID: 30935579. doi:10.1016/j.radonc.2018.12.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。